Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser

doi:10.3390/healthcare1010096

Open AccessThis article is

freely available
re-usable

Healthcare 2013, 1(1), 96-99; doi:10.3390/healthcare1010096

Case Report

Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser

Michael Z. Wang and Jerry D. Brewer *

Department of Dermatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA

* Author to whom correspondence should be addressed.

Received: 20 August 2013; in revised form: 16 October 2013 / Accepted: 21 October 2013 / Published: 25 October 2013

Download PDF Full-Text [593 KB, uploaded 25 October 2013 15:06 CEST]

Abstract: No particular regimen is considered standard therapy for widespread metastatic melanoma, although surgery is the primary choice for regional nodal metastases. Systemic interleukin-2 (IL-2) is an effective immunotherapy for melanoma, but standard doses are associated with severe toxicity. We report a patient who was treated with intralesional low-dose IL-2 and V-beam pulsed dye laser for the treatment of scalp melanoma metastases. This treatment resulted in rapid regression of metastatic tumors with limited adverse effects.

Keywords: interleukin-2; melanoma; pulsed dye laser therapy

Article Statistics

Load and display the download statistics.

Citations to this Article

Load and display citations from CrossRef.

Cite This Article

MDPI and ACS Style

Wang, M.Z.; Brewer, J.D. Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser. Healthcare 2013, 1, 96-99.

AMA Style

Wang MZ, Brewer JD. Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser. Healthcare. 2013; 1(1):96-99.

Chicago/Turabian Style

Wang, Michael Z.; Brewer, Jerry D. 2013. "Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser." Healthcare 1, no. 1: 96-99.

Healthcare EISSN 2227-9032 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert